Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Erbitux

Erbitux 5 mg/mL solution for infusion · Abschnitt 4.8 · PDF-Seite 10–11

HOS-113176 · Präparat HOS-093871

10  Cetuximab Cetuximab in Cetuximab in combination combination with with Encorafenib and Encorafenib FOLFOX (n = 216) (n = 259) Investigations Very common Lipase increased* Weight decreased Transaminase increased* Common Blood creatinine Blood creatinine increased* increased* Amylase increased* Transaminase increased* Uncommon Amylase increased Lipase increased Metabolism and Nutrition disorders Very common Hypomagnesaemia (see Decreased appetite Decreased appetite section 4.4). Hypokalaemia Hypomagnesaemia Hypoalbuminaemia* Common Dehydration, in particular secondary to diarrhoea or mucositis Hypocalcaemia (see section 4.4) Anorexia which may lead to weight decrease Musculoskeletal and connective tissue disorders Very common Arthralgia/Musculoskelet Arthralgia/Musculoskeletal al pain* pain* Myopathy/ Myopathy/ Muscular disorder* Muscular disorderd Pain in extremity Back pain* Back pain Common Pain in extremity* Neoplasms benign, malignant and unspecified Very common Melanocytic naevus Common cuSCCe Melanocytic naevus Skin papilloma* Skin papilloma* New Primary Melanoma* Basal cell carcinoma cuSCCe Uncommon Basal cell carcinoma* New Primary Melanoma* Nervous system disorders Very common Neuropathy peripheral* Neuropathy peripheralf Headache* Dysgeusia* Headache* Common Headache Dizziness* Dizziness* Dysgeusia Unknown Aseptic meningitis Psychiatric disorders Very common Insomnia Insomnia* Renal and urinary disorders Common Renal failure* Renal failure* Respiratory, thoracic and mediastinal disorders Uncommon Pulmonary embolism Interstitial lung disease, which may be fatal (see section 4.4)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.